Wall Street Bullish on Soleno Therapeutics Ahead of Key FDA Decision
Published on 12/07/2025 at 07:31 | Redaktion boerse-global.de
While shares of Soleno Therapeutics saw minimal movement in Friday’s trading session, closing with a slight decline, this surface-level calm belies a significant surge of confidence emanating from Wall Street. Multiple market analysts are highlighting substantial potential in the biotechnology firm, pointing to a major upcoming regulatory catalyst.
The company’s primary focus is developing therapies for rare diseases. Its most closely watched program is the drug candidate DCCR for Prader-Willi syndrome, a condition that currently lacks any approved pharmacological treatments.
The U.S. Food and Drug Administration (FDA) has set a target action date of March 27, 2025, for its decision on the drug’s approval. This date represents a Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
